Proprietary & confidential · Not for redistribution
The Clinical Toolkit · v1.0
On call. On hand. In practice.
Four tools for the functional medicine prescriber working inside an aesthetic
or wellness practice. Built from clinical workflow up. Not curriculum down.
LicenseSingle-user, perpetual
HostedUltrawell Academy
Last updateMay 2026
→
The Four Tools
→
How to Use This
The toolkit is built around one habit: open the tool you need and set patient
context where it matters. Lab Review and Chairside Reference filter their
content by patient. Set context once at the top of those tabs and every
relevant flag surfaces first.
01Open Lab Review
Set patient context at the top, upload labs or enter values manually.
Get scoring, pattern detection, and a printable summary.
02Cross to Chairside
Patient context carries across. The relevant symptom cards and patient
scripts surface first.
03Confirm in Protocols
Branching decision trees with dosing, monitoring intervals, and
titration logic. Export a clean note to the chart.
04Close the Loop
The Practice tab handles consent, follow-up, and the next consult.
Nothing falls off the back of the desk.
→
A Note on This License
Welcome. This toolkit was built with clinicians, for clinicians. Designed
to be a working partner in your practice, not a static reference. The
protocols inside started in our clinic, sharpened through real cases, and
they will keep sharpening as alumni bring them into the field. Your
feedback informs the next version. Your wins become teaching for the
cohort behind you. We are in this together.
That collaboration only works when the work stays protected. This toolkit is
provided to enrolled Ultrawell Academy members for their own clinical use. It runs
entirely in your browser — no patient data leaves the page, and it will keep
working as the protocols inside continue to sharpen with each cohort.
License terms & enforcement
This toolkit is the proprietary and confidential intellectual property of Ultrawell
Academy. Sharing, copying, redistributing, reselling, sublicensing, or
reproducing this file or any portion of its contents — in any form, to any party —
is prohibited, terminates your access immediately, and constitutes a violation of
United States copyright law (17 U.S.C. § 501 et seq.). Ultrawell Academy
reserves the full range of legal remedies, including statutory damages, attorney's
fees, and injunctive relief.
01
Lab Review
How to Use This Tool
This is a functional-medicine lab interpretation engine. Enter your patient's lab values by hand into the matching fields below — each result is scored against optimal functional ranges, not just standard lab reference ranges.
Set the patient context (sex, age, hormonal status) in the dark bar below — several ranges adjust automatically by sex, and the lipid risk tier drives the LDL / ApoB targets.
Type each value into its field. Scoring, calculated ratios (HOMA-IR, fT3:rT3, etc.), and the color tier update live as you go.
Watch the Terrain Pillar scores and Pattern Clusters build at the top — they synthesize the individual markers into the bigger picture.
Only enter the values you have. Blank fields are simply skipped — nothing is penalized for being left empty.
Clinical decision-support only. Always interpret in the context of the whole patient, not a single number.
What You Get Back
Terrain Pillar Scoring
Metabolic, inflammatory, hormonal, cardiovascular, hepatic, nutritional, immune. Five-tier color scoring at a glance.
Pattern Clusters
Seven clusters surface from the data: cardiometabolic, thyroid, anemia/iron, inflammatory, insulin resistance, hepatic, female iron triad.
🫀TG ≥150 mg/dL — 2026 treatment options: fenofibrate (−30-50% TG, +5-15% HDL) or icosapent ethyl / Vascepa (−25% TG, CVOT evidence) when residual risk after statin. Address insulin resistance, dietary carb load, and alcohol first. Recheck after 8-12 weeks of lifestyle intervention before adding pharmacotherapy.
🧬Lp(a) ≥50 mg/dL — high genetic risk: 2026 Class 1 recommendation is to test once per lifetime (80-90% genetic). Elevated Lp(a) raises ASCVD risk independently of LDL. Treat by aggressively lowering ApoB / LDL (statin + ezetimibe ± PCSK9 inhibitor) since Lp(a)-specific agents are emerging but not yet first-line. Consider family screening.
⚠️Biotin supplementation can falsely elevate Free T3, Free T4, and suppress TSH. Confirm patient is not taking biotin within 48–72 hrs of blood draw before interpreting thyroid results.
TSH mIU/L
AUTO
—
1.0–2.0 optimal0.4–4.5 lab ref
Free T3 pg/mL
AUTO
—
3.2–4.2 optimal2.3–4.2 lab ref
Free T4 ng/dL
—
1.0–1.5 optimal0.8–1.8 lab ref
Reverse T3 ng/dL
—
<15 optimal<24 lab ref
TPO Antibodies IU/mL
—
<9 optimal<35 lab ref
fT3:rT3 Ratio CALC
—
>20 optimal>10 standard
Hormones — Adrenal
HPA axis assessment
HPA Axis Assessment
Not started▼
Morning Cortisol µg/dL
—
10–18 optimal AM6–23 lab ref
ACTH pg/mL
—
10–50 optimal7–63 lab ref
Inflammation / Oxidative Stress
Inflammatory biomarkers
Inflammatory Biomarkers
Not started▼
hsCRP mg/L
AUTO
—
<0.5 optimal<3.0 lab ref
Homocysteine µmol/L
AUTO
—
<7 optimal<15 lab ref
Ferritin ng/mL
AUTO
—
M: 50–100 optimalF: >70 optimal
TIBC µg/dL
—
250–370 optimal250–370 lab ref
Iron Saturation % CALC
—
20–35% optimal15–50% lab ref
Uric Acid mg/dL
—
<5.5 optimalM:<8.5 F:<7.0
Nutrients / Micronutrients
Essential micronutrient panel
Essential Micronutrient Panel
Not started▼
Vitamin D (25-OH) ng/mL
AUTO
—
60–80 optimal30–100 lab ref
Vitamin B12 pg/mL
AUTO
—
>600 optimal200–900 lab ref
Folate ng/mL
—
>15 optimal>3.4 lab ref
RBC Magnesium mg/dL
—
5.6–6.8 optimal4.2–6.8 lab ref
Zinc µg/dL
—
90–120 optimal60–130 lab ref
Omega-3 Index %
—
>8% optimal>4% standard
CBC / Differential
Complete blood count with full differential — sex-specific ranges applied
Complete Blood Count — Pattern Analysis
Not started▼
🩸TRT/testosterone therapy: HCT >55% is a clinical flag. Consider therapeutic phlebotomy and/or dose adjustment. Confirm HCT in context of hydration status.
WBC ×10³/µL
—
5.0–7.5 optimal4.5–11.0 lab ref
RBC ×10⁶/µL
—
M: 4.7–5.7F: 4.2–5.2
Hemoglobin g/dL
—
M: 14–17F: ≥14 optimal
Hematocrit %
—
M: 42–50 · >55 FLAGF: ≥40% optimal
MCV fL
—
82–90 optimal80–100 lab ref
MCH pg
—
27–33 optimal27–33 lab ref
MCHC g/dL
—
32–36 optimal32–36 lab ref
Platelets ×10³/µL
—
175–350 optimal150–400 lab ref
Neutrophils %
—
50–65% optimal40–75% lab ref
Lymphocytes %
—
25–40% optimal20–45% lab ref
Monocytes %
—
6–8% optimal2–8% lab ref
Eosinophils %
—
<3% optimal<5% lab ref
Basophils %
—
<1% optimal<1% lab ref
NLR CALC
—
<2.5 optimal<3.0 standard
⚖️Differential values are relative percentages. Because they sum to ~100%, a low neutrophil percentage mathematically inflates monocytes, lymphocytes, and other fractions without any true change in their absolute counts. With neutrophils running low, interpret an elevated monocyte or lymphocyte percentage in context and confirm against absolute counts before flagging.
Liver / Detox
Hepatic function panel
Hepatic Function Panel
Not started▼
💪Elevated AST/ALT may reflect intense resistance exercise rather than hepatic pathology. Confirm recent exercise history before interpreting liver enzyme elevation.
ALT U/L
—
<25 optimal<56 lab ref
AST U/L
—
<25 optimal<40 lab ref
GGT U/L
—
<20 optimal<65 lab ref
AST:ALT Ratio CALC
—
<1.0 typical>2.0 concern
Kidney
Renal function panel
Renal Function
Not started▼
⚠️Creatine supplementation raises serum creatinine, which may artificially lower calculated eGFR. If patient takes creatine, consider Cystatin C-based eGFR for more accurate assessment.
Creatinine mg/dL
—
0.8–1.1 optimal0.7–1.3 lab ref
BUN mg/dL
—
12–18 optimal7–25 lab ref
eGFR mL/min/1.73m²
—
>90 optimal>60 lab ref
Cystatin C eGFR mL/min/1.73m²
—
>90 optimal>60 lab ref
BUN:Creatinine Ratio CALC
—
10–20 optimal6–22 lab ref
Detected Patterns
Auto-detected clinical clusters based on entered values
Enter lab values above to detect clinical patterns.
Clinical Questions
Context-driven prompts generated from entered values
Clinical prompts will appear as values are entered.
Body Composition
Biometrics · BMI · Composition scoring
Patient Biometrics
Not started▼
Anthropometrics
Height in
Weight lbs
BMI AUTO
Waist in
Hip in
Waist:Hip Ratio AUTO
Body Composition
Visceral Fat Display
Visceral Fat Rating 1–20
Visceral Fat Area cm²
Body Fat % PBF
Skeletal Muscle Mass lbs
SMI AUTOkg/m²
ECW/TBW Ratio
Composition Score
Composition Scoring
Enter values above to generate composition scores.
Metabolic Syndrome Assessment
Not started▼
Enter biometrics and lab values (glucose, TG, HDL, BP) to assess metabolic syndrome criteria.
Systolic BP mmHg
Diastolic BP mmHg
Medications & Supplements
Drug database search · Interaction flags · Depletion alerts
⚠ Clinical Decision-Support Disclaimer: Flags shown below are clinical prompts intended for licensed practitioners to assist in pattern recognition. They do not constitute prescriptive guidance, clinical recommendations, or a substitute for professional clinical judgment. All drug-nutrient depletion and interaction alerts should be verified against current clinical references before acting.
⚡ Requires age, sex, height, weight from patient bar + LBM from Body Composition tab. Mifflin-St Jeor formula. Decrease refined carbohydrates, fructose, and ultra-processed foods regardless of targets.
Value at T0 vs latest visit · Change shown with direction
Delta Comparison▼
Marker
Baseline (T0)
Latest Visit
Δ Change
Status
Enter a second visit to generate delta comparisons
Clinical Narrative
Auto-generated objective assessment · Chart note format
Visit-to-Visit Summary▼
OBJECTIVE ASSESSMENT — AUTO-GENERATED
Click "Generate" above after entering at least one visit to produce an AI-drafted clinical summary of changes between visits. Output is formatted for direct use in chart notes.
Export & Branded Report
Ultrawell branded PDF · White-label upgrade · Credentials auto-stamped
Branding
Report Style
Provider Name
License / NPI (auto-stamped)
Practice Name
Include in Report
Generate
Provider license & credentials auto-stamped on all reports
Report PreviewLIVE PREVIEW
ULTRAWELL
Lab Intelligence Report
Provider: —
License: —
Patient: — | Sex: — | Age: — | Goal: —
Metabolic / Glycemic
Terrain Pillar Scores
02
Chairside Reference
Six sub-tabs, organized for the workflow at the chair. Symptom Triage opens
with eleven differentials; the four hormone tabs run quick reference, common
concerns, risks versus reality, red flags, and monitoring; and Injection
Reactions is the deep reference for testosterone and peptide site reactions.
Patient-facing language is preserved throughout, framed for direct use.
2.1Symptom Triage
Eleven differentials, each opening with the questions to anchor history, the
three-tier action call, the clinical context that frames the decision, and
patient-facing language.
Unscheduled Bleeding
Spotting, breakthrough, or any bleeding the patient wasn't expecting on HRT.
History: anchor questions
Onset and duration of the bleeding.
Character: spotting, light flow, period-like.
Time on current regimen, and any recent dose change.
Progestogen adherence: taken exactly as prescribed.
History of fibroids, polyps, or abnormal Paps.
Manage in clinic
First 6 months on HRT or within 3 months of a dose change, intermittent spotting/light bleeding, no risk factors. Common and usually resolves with progestogen adjustment. Reassure, document, schedule routine follow-up. BMS '24
Investigate this week
Bleeding persisting beyond 6 months on stable HRT, recurring after previously settling, heavy bleeding, or any concerning context (BMI > 30, family history of endometrial or colon cancer, tamoxifen use, diabetes). Order TVUS. BMS '24
Escalate today
Heavy bleeding with clots, bleeding plus pelvic pain, fever, dizziness, or pregnancy-possible patient. Same-day evaluation. Hemodynamically unstable → ED.
Bleeding can feel scary, and I'm glad you reached out. Some spotting in the first three to six months of hormone therapy is actually really common. Your uterine lining is adjusting to the new signal. Given how long you've been on therapy, I want to take a closer look at the timing. Depending on what we see we may adjust your progesterone or get a quick ultrasound just to be thorough. Any pain with the bleeding?
Never minimize. Get the timeline, document everything. BMS 2024 algorithm: under 6 months → adjust progestogen; over 6 months → image.
Why this is usually not cancer
The risk of endometrial cancer in women with unscheduled bleeding on HRT is significantly lower than the risk in women with postmenopausal bleeding not on HRT. The progestogen is doing its protective job. Most bleeding is mechanical. Endometrium adapting to the hormonal signal. BMS '24
Weight Changes
"I'm gaining weight on HRT". One of the most common and most misunderstood concerns.
History: anchor questions
How much weight, over what timeframe.
Distribution: belly/midsection, or generalized.
Appetite, sleep, energy, stress changes.
Temporal relationship to HRT start.
New medications (GLP-1s, antidepressants, steroids).
What the evidence actually says
Menopausal hormone therapy does not cause weight gain. Multiple prospective cohorts (OsteoLaus, Danish Osteoporosis Prevention Study) show HRT prevents the menopause-associated gain in visceral fat and may attenuate total fat mass gain. OsteoLausSites '05
Mechanism: estrogen decline at menopause drives redistribution of fat to the abdomen (visceral fat goes from ~5–8% to 15–20% of total fat in postmenopausal women). HRT counteracts this. Patients conflate menopause-driven changes with the start of HRT.
Manage in clinic
Modest changes (under 5–7 lbs), clear stressors or lifestyle drivers, normal energy and sleep. Reassure with evidence, dietary and movement check-in, document.
Investigate
Rapid gain (10+ lbs in < 6 months), fluid retention pattern, brain fog, fatigue, hair changes. Recheck thyroid and reassess hormone regimen. Consider GLP-1 conversation if metabolic.
I hear this concern a lot, and I want to share something most patients don't know: HRT actually prevents the kind of belly weight gain that comes with menopause. There's solid research on that. What you're feeling is real, but it's almost certainly the menopause itself, not the therapy. Let's check a few things together. Sometimes thyroid or stress is the real driver, and labs will tell us whether a piece of your regimen needs adjusting.
Never validate "HRT made me gain weight". The data don't support it. Validate the experience while reframing the cause.
Fatigue
Persistent tiredness. Could be hormonal, thyroid, sleep-driven, or nutrient/metabolic.
History: anchor questions
Onset and character: physical, cognitive, or both.
Persistent > 2 weeks, functional impairment, accompanied by other symptoms. Full hormone and thyroid workup.
Escalate today
Fatigue plus chest pain, shortness of breath, leg swelling, syncope, or new severe headache. Cardiac/PE/CNS workup, not a hormone call.
Fatigue is one of those symptoms that can come from a few different places. Thyroid, hormones, sleep, stress, or sometimes nutrition. Tell me a little more about the pattern. Is it more morning, afternoon, or all day? How is your sleep? That'll help me figure out where to dig in first.
Don't promise it's "definitely your hormones." Triage first. Most fatigue presentations need a broader workup.
Mood, Anxiety, Depression
New or worsening emotional symptoms on or around hormone therapy.
Temporal relationship: before or after starting/changing HRT.
Progesterone formulation, route, and timing.
Sleep, alcohol, recreational drugs, stress.
Safety screen: any thoughts of self-harm.
Progesterone intolerance is real
Most patients find micronized progesterone calming and sleep-supportive (via the GABA-active metabolite allopregnanolone). A subset experience the opposite. Anxiety, agitation, low mood, or sleep disruption. This is paradoxical progesterone intolerance, not a "side effect to push through."
Options for these patients: vaginal route (lower systemic absorption), LNG-IUD for endometrial protection, or in some cases switching to estrogen-alone if hysterectomy is in their past.
Investigate this week
New mood symptoms that started with HRT, especially if progesterone-related. Consider route change or alternative endometrial protection.
Escalate today: 988 if needed
Any mention of suicide, self-harm, or wanting to "not be here." Do not end the encounter without a plan. 988 (Suicide & Crisis Lifeline) is appropriate to share. Document everything.
Thank you for telling me. Mood changes can absolutely be related to hormones. And sometimes they're a sign that one piece of your regimen needs adjusting. There's a real thing called progesterone intolerance where the progesterone makes some women feel more anxious, not less. Let's look at your regimen together and figure out what to change. And before we go further. Are you safe right now?
Always ask the safety question. Always.
Low Libido
Low desire, reduced arousal, or distress about sexual function.
History: anchor questions
Duration of the change.
Desire, arousal, or both.
Pain with intercourse (GSM signal: see card).
Relationship factors, stress, sleep, mood.
Current medications: SSRIs, beta blockers, OCPs.
The clinical model for HSDD
Hypoactive sexual desire disorder (HSDD) is the only evidence-based indication for testosterone therapy in women. The ISSWSH 2019 Global Consensus supports transdermal testosterone at doses targeting physiologic premenopausal levels. ISSWSH '19
Glaser's body of work also documents that testosterone alone relieves nearly all menopausal symptoms including hot flashes (Sherwin 1985: T > T+E2 > E2 > placebo). GlaserSherwin '85
Always rule out GSM as a contributor before assuming pure desire issue. Pain with intercourse will erode desire.
Investigate
Persistent low desire with distress. Order hormone panel (Total T, Free T, SHBG, E2, DHEA-S) and discuss testosterone therapy or pellet options.
This is one of the most common things I hear and one of the most treatable. Testosterone is often a missing piece for women, and there are several routes we can take. Before we decide on anything, let's run baseline labs. Total and free T, SHBG, estradiol, DHEA-S, so we know what we're working with.
Pre-pellet labs: FSH, E2, free T, total T (Glaser protocol). Female testosterone dosing references and conversion tools land in Protocols.
Sleep Disturbance
Insomnia, fragmented sleep, or night-time wakings on hormone therapy.
History: anchor questions
Onset insomnia, maintenance insomnia, or early waking.
Night sweats waking the patient.
Progesterone timing: AM vs bedtime.
Wake time pattern: 3am wakings.
Caffeine, alcohol, screens before bed.
Progesterone is a sleep tool, when timed right
Oral micronized progesterone is sedating because its metabolite allopregnanolone is GABAergic. Always take at bedtime, never in the morning. If a patient is dosing AM, that alone may be the issue.
If patient is on bedtime progesterone and still can't sleep: consider (a) night sweats from undertreated estradiol, (b) anxiety/cortisol dysregulation (3am wake-ups are classic), (c) sleep apnea (especially with weight gain or snoring).
Manage in clinic
Patient taking progesterone in AM → switch to bedtime. Sleep hygiene basics. Recheck in 2 weeks.
Investigate
Night sweats waking patient despite HRT. Likely estradiol underdose. Cortisol pattern (3am wakings, racing thoughts). Broader workup. Consider sleep study if apnea features.
Real quick. What time of day are you taking your progesterone? Because it works best at bedtime; for a lot of women it's actually their sleep aid. If you're taking it in the morning, that might be the whole fix. Try it at bedtime tonight and let's see how the next few nights go.
This is a "you can fix it on the phone" call about 30% of the time. Always ask about progesterone timing first.
Hot Flashes / Night Sweats
Vasomotor symptoms. Either new, persistent, or returning on HRT.
History: anchor questions
Time on current dose.
Daily flash count and severity.
Whether flashes ever resolved on HRT and have returned.
Patch / gel application consistency.
Adhesion issues, skin reactions.
Timeline of vasomotor response
Most patients see meaningful reduction within 2–4 weeks of starting effective-dose estradiol; full effect by 8–12 weeks. If patient is < 6 weeks in, reassure and wait. NAMS '22
If patient is > 12 weeks in with persistent flashes, dose is likely insufficient. Target serum estradiol ~50–100 pg/mL for VMS control; transdermal 0.05 mg patch is often the floor, with 0.075–0.1 mg needed in some patients.
If relief was achieved and lost. Check patch adhesion, application site rotation, or whether the prescription was switched at the pharmacy.
Manage in clinic
< 6 weeks on therapy, mild flashes, otherwise well. Reassure timeline. Confirm correct patch application and site rotation.
Investigate
> 12 weeks on therapy with persistent flashes, or relief lost. Reassess dose.
Hot flashes usually start improving by about 2 to 4 weeks and are fully under control by 2 to 3 months. If you're still in that window, we want to give it a little more time. If you're past 3 months and still flashing, we probably need to bump your dose. And that's an easy conversation. Walk me through how you're using your patch.
Application site rotation matters. Same-site daily reduces absorption over time.
Breast Tenderness
Soreness, fullness, or sensitivity that started or worsened on HRT.
History: anchor questions
Onset: within first weeks of HRT, or out of the blue.
Distribution: unilateral or bilateral, generalized or focal.
Lumps, skin changes, or nipple discharge.
Last mammogram.
Caffeine intake.
Initial vs. dose-excess vs. red flag
First 2–6 weeks on HRT: Common, mild, bilateral. Tissue is responding to estrogen. Usually self-resolves.
Persistent or new tenderness after stable HRT: Often indicates dose excess. Step down the patch by one strength.
Focal, unilateral, with a lump, dimpling, nipple discharge, or skin changes: Imaging-warranted. Not an HRT issue. A breast issue.
Manage in clinic
First 6 weeks, mild, bilateral, no focal findings. Reassure, reduce caffeine, supportive bra. Recheck in 2–4 weeks.
Investigate
Persistent after 6 weeks, or new tenderness after established HRT. Consider dose reduction.
Escalate this week
Lump, dimpling, nipple discharge, skin changes, or any focal finding. Imaging-warranted regardless of HRT status. Same-week imaging.
Some breast tenderness in the first month or so is really common. The tissue is just adjusting. If it's mild and on both sides, it usually settles down. But if you're feeling a lump, or skin changes, or anything one-sided, I want to get you in sooner. That's a separate conversation from your hormones. How are you feeling about that?
Always separate the HRT question from the breast lump question. They are not the same call.
Headache
New, worsening, or pattern-changed headaches on hormone therapy.
Pattern: cyclic, around dose change, around bleed.
Migraine history, especially with aura.
Route: oral, patch, gel.
Oral vs. transdermal matters
Estrogen-fluctuation headaches are more common with oral estradiol (higher peak-trough swings, first-pass effect). Steady-state transdermal often resolves them. NAMS '22
Migraine with aura is the classic red flag for systemic estrogen. Historically a contraindication. Modern thinking: transdermal at low dose is increasingly considered safe in migraine-with-aura patients because it avoids the supraphysiologic peaks that drive vascular events. Always provider-decision and shared with patient.
Investigate
New cyclic pattern, dose-change correlation, or oral estradiol user with worsening headaches. Switch routes or adjust dose.
Escalate today / ED
"Worst headache of my life," sudden severe onset, headache + vision loss / weakness / slurred speech / one-sided numbness. CVA workup, not a hormone call. ED.
Headaches and hormones do interact, especially around dose changes or the type of estrogen you're on. The transdermal patch is usually easier on headaches than oral. Let's plan to look at that. But first, are you having any vision changes, weakness, or trouble speaking with the headache? Anything like that, we need to take more seriously today.
Always rule out stroke symptoms before any routine plan.
Vaginal Dryness / GSM
Genitourinary syndrome of menopause. Dryness, painful intercourse, recurrent UTIs.
Breast cancer history: on tamoxifen or an aromatase inhibitor.
Local vaginal estrogen is the answer, even for many BC survivors
Local vaginal estrogen (estradiol cream, estradiol ring, estradiol tablets, or vaginal estriol) has minimal systemic absorption and is the treatment of choice for GSM. Systemic HRT does not always control GSM; many patients need local treatment added on. NAMS '22
Breast cancer survivors: Recent data show vaginal estrogen does not increase breast cancer recurrence in survivors on tamoxifen. Aromatase inhibitor users are more nuanced. Recurrence data conflicting, mortality data reassuring. Vagifem 10mcg is the lowest-systemic option. Glaser also supports vaginal estriol as an even safer alternative in BC survivors. Glaser
Non-hormonal options (hyaluronic acid moisturizers, Replens) help adjunctively but don't address the atrophy.
Investigate / treat
Any GSM symptom bothering the patient. Highly treatable. Local estrogen prescription, with formulation choice driven by BC history.
This is one of the most treatable things in menopause, and most patients don't bring it up. So I'm glad you did. We have several options, including a very low-dose local cream or tablet that stays in the vaginal tissue and doesn't behave like a systemic hormone. Even patients who can't take systemic HRT can usually use it. Let's plan a treatment together.
If patient has breast cancer history, lead with the safer local options (Vagifem 10mcg, vaginal estriol) and frame this as a quality-of-life conversation worth having.
Injection Site Reaction
Redness, itching, swelling, or pain at testosterone or other injection sites.
History: anchor questions
What's at the site: itching, redness, swelling, heat, pain.
Itch only, no heat or pain, local hives, onset 30 min – several hours, resolves in 24–48 hours, same as prior injections. Cold compress, oral antihistamine (loratadine or cetirizine), rotate sites, document.
Investigate / pause
Getting worse with each dose, timing shifted to faster onset, spreading beyond injection zone, lasting > 48–72 hrs, or started with a new vial/lot. Pause protocol, review formulation (oil/carrier switch).
Escalate today
Heat + pain at site, spreading redness > 5 cm, fever or chills, pus or skin breakdown, wheezing, throat tightening, dizziness. Systemic = 911. Heat + fever + pain = ED or urgent care. Do not just add more antihistamine.
The antihistamine diagnostic test
Take a standard dose of loratadine or cetirizine when the reaction begins. Wait 60–90 minutes. Significantly better → histamine-mediated, formulation/technique issue, manageable. No improvement → something else is happening; possible infection or cellulitis, escalate.
Walk me through what you're seeing. Is it itchy only, or is there real heat and pain there? Any fever or chills? Those last two things are important. Itching and a welt is usually a histamine reaction we can manage, but heat, pain, and fever can mean infection, which is a different conversation. Try an antihistamine and see if it improves in an hour. And reach back out if it gets worse or doesn't get better.
The antihistamine test is the cleanest triage. If it works, it's histamine. If it doesn't, escalate.
2.2Estradiol
The estradiol reference: route hierarchy, dose targets, the conversations
patients arrive with, and where current evidence parts ways with
old dogma.
2.2.1Quick Reference
Preferred Routes
Transdermal First
Patch (Vivelle-Dot, Climara, Minivelle) or gel (Estrogel, Divigel). Bypasses first-pass hepatic metabolism, neutral on VTE risk, more physiologic E2-to-estrone ratio.
Oral
Reserved for patient preference where transdermal isn't tolerated, or where patch adhesion fails consistently. Always discuss the VTE tradeoff.
Local Vaginal
For GSM, independent of systemic regimen and can be added on. Vagifem 10mcg or vaginal estriol preferred when systemic concern exists.
Route
Typical Starting Dose
Approx Serum E2
Notes
Patch
0.025–0.05 mg/day (twice weekly)
35–55 pg/mL
Vivelle-Dot, Climara, Minivelle. Rotate sites.
Gel
0.5–1.0 mg/day
40–80 pg/mL
Estrogel, Divigel. Apply to clean dry skin, wash hands.
Bone protection: ~50–60 pg/mL or higher (0.05 mg patch floor).
Full symptom relief (mood, libido, cognition): Often 60–100+ pg/mL. Individualize.
2.2.2Common Concerns
"Will I gain weight on estrogen?"
No. Multiple cohort studies (OsteoLaus, Danish Osteoporosis Prevention Study) show estrogen therapy prevents the menopause-associated gain in visceral fat. Weight gain at menopause is from declining estrogen. HRT counteracts it. OsteoLaus
"My mother had breast cancer. Is HRT safe for me?"
Family history is not an absolute contraindication. Many patients with strong family history can safely use HRT, especially transdermal estradiol with micronized progesterone. Review the specific family history and any genetic testing. NAMS '22
The 2024 WHI reanalysis found that estrogen alone (in hysterectomized women) actually reduced breast cancer incidence (HR 0.77) and mortality by 40%. This is the most underreported finding in the field. WHI Reanalysis '24
"How long can I stay on it?"
No arbitrary stop date. NAMS 2022 explicitly removed time-limit recommendations. Continuation is individualized. Risk-benefit is reassessed periodically, but many women safely stay on HRT indefinitely if symptoms recur on discontinuation. NAMS '22
"My cardiologist / oncologist / GYN said I should stop."
Common scenario. Patient hears advice from a subspecialist that doesn't match current menopause/HRT evidence. Don't argue with the other provider in front of the patient. Bring the patient back in to review the specifics and offer a collegial conversation if needed.
2.2.3Risks vs. Reality
The estrogen conversation is shaped by a 2002 WHI study that used conjugated equine estrogens + medroxyprogesterone acetate in women whose average age was 63. Modern evidence has separated out variables WHI conflated. Here's where to push back without overreaching.
×
Old Dogma
"All estrogen therapy increases the risk of blood clots."
✓
Current Evidence
Oral estrogen increases VTE risk 1.6–1.9× via first-pass hepatic effects on thrombin generation and activated protein C resistance. Transdermal estradiol is essentially neutral (RR ~1.0) confirmed by ESTHER, E3N, and multiple meta-analyses. The route matters more than the molecule. ESTHERE3NMohammed/Murad '15
×
Old Dogma
"HRT causes breast cancer."
✓
Current Evidence
The signal came from CEE + medroxyprogesterone acetate. In the WHI estrogen-alone arm (hysterectomized women), estrogen reduced breast cancer incidence (HR 0.77) and breast cancer mortality by 40%. Estradiol + micronized progesterone (the modern combination) shows much weaker signal. Micronized P has RR ~0.67 for breast cancer vs synthetic progestins. WHI Reanalysis '24Asi '16
×
Old Dogma
"HRT causes dementia."
✓
Current Evidence
The WHI Memory Study (WHIMS) gave HRT to women aged 65+ who were a decade past menopause. Wrong window. Timing is everything. HRT initiated within 5–10 years of menopause is associated with reduced dementia risk. Late initiation (10+ years out) is where the increased risk shows up. The "critical window" hypothesis is now well-supported. APOE-ε4 carriers are an exception. Buckley '23Coughlan '23
×
Old Dogma
"HRT causes weight gain."
✓
Current Evidence
HRT does not cause weight gain. Multiple cohort studies show it prevents the menopause-associated gain in visceral fat (which goes from ~5–8% to 15–20% of total fat without intervention). The weight gain women see during the menopause transition is from declining estrogen, not its replacement. OsteoLaus
2.2.4Red Flags & Escalation
!
Same-day escalation
Chest pain, shortness of breath, or new-onset cough
One-sided leg swelling, calf pain, or warmth (DVT signs)
Sudden severe headache: "worst headache of my life"
New visual changes, weakness, slurred speech, one-sided numbness
Heavy vaginal bleeding with clots, pelvic pain, fever
Unilateral breast lump, dimpling, or nipple discharge
Right upper quadrant pain (gallbladder, especially with oral estrogen)
Skin yellowing, dark urine, or pale stool (hepatic signs)
2.2.5Monitoring Timeline
Timepoint
What Happens
Patient-Facing Framing
Week 1–2
Initial side effects peak (breast tenderness, bloating, mild headache)
"Hang in there. Your body is adjusting. These usually settle by week 4."
Week 2–4
Vasomotor symptoms start improving
"Hot flashes should start easing. Reach out if no change by week 6."
Week 6
First check-in. Symptom review, side-effect review.
"This is when we look at whether the dose is right for you."
Month 3
Full effect on VMS; consider dose adjustment if incomplete relief
"By 3 months, you should know if this is the right dose."
Month 6
Follow-up labs if indicated. Symptom check.
"We'll repeat your labs and make sure everything is on track."
Annual
Full review. Mammogram per age-appropriate screening. Bone density per age.
"Once a year we review the whole picture and adjust as your needs change."
Note on serum estradiol monitoring
Measuring estradiol levels supports dose titration and patient reassurance. Not every practice does this. Frame it as: "We measure where your hormone level actually lands, because the dose on the patch doesn't always match what your body absorbs."
2.3Progesterone
The progesterone reference: the micronized molecule, the bedtime rule, and
the cleanest evidence we have for choosing micronized progesterone over
synthetic progestins.
2.3.1Quick Reference
Preferred Routes
Oral Micronized, at Bedtime
Prometrium or generic. The default. The GABA-active metabolite supports sleep, and it is well-tolerated by most.
Vaginal Micronized
When oral is poorly tolerated (paradoxical anxiety, daytime sedation). Same molecule, lower systemic, direct uterine effect.
LNG-IUD (Mirena, Liletta)
An alternative endometrial protection strategy for patients who can't tolerate progesterone at all. Five-year duration.
Synthetic Progestins
Medroxyprogesterone, norethindrone. Not preferred. The breast cancer signal in WHI came from MPA; modern data favor micronized.
Regimen
Dose
Schedule
Best For
Continuous combined
100 mg/night
Every night
Postmenopausal, want amenorrhea, established HRT
Sequential (cyclic)
200 mg/night
12–14 nights/month
Perimenopausal, still ovulating, expect a withdrawal bleed
Oral micronized progesterone metabolizes to allopregnanolone, a positive allosteric modulator at the GABA-A receptor. This is why it's sedating. Patients who take it in the morning report grogginess and feeling "drugged". But the same dose at bedtime is one of the best sleep aids in the menopause toolkit. Always confirm timing before assuming intolerance.
2.3.2Common Concerns
"It makes me anxious / agitated / depressed."
Paradoxical progesterone intolerance is real and affects a meaningful minority of patients. The mechanism is poorly understood but likely involves GABA receptor subtype variation. This is not a "push through it" side effect. Options: switch to vaginal route (lower systemic exposure), reduce the dose if continuous, or use LNG-IUD for endometrial protection. Do not insist on oral micronized in patients who feel worse on it.
"I feel groggy in the morning."
Usually means the dose is hitting too late in the night, or the patient took it too close to wake-up. Move it earlier in the bedtime window (60–90 min before sleep). If persistent, consider 100 mg instead of 200 mg, or switch route.
"Do I really need it if I had a hysterectomy?"
For endometrial protection. No. After hysterectomy, progesterone is not required for safety. However, some patients still benefit from progesterone for sleep, mood, and CNS effects. This is a quality-of-life decision, not a safety requirement.
"Can I skip nights?"
No, not on continuous combined regimens. The progesterone is doing endometrial protection. Gaps in dosing allow estrogenic stimulation without opposition, increasing breakthrough bleeding and (long-term) endometrial hyperplasia risk. If timing is a problem, address timing. Not adherence.
2.3.3Risks vs. Reality
The progesterone conversation is where evidence and patient anxiety diverge most. The breast cancer signal that defines public perception came from synthetic progestins. Not the micronized progesterone we use. The distinction matters.
×
Old Dogma
"Progesterone causes breast cancer."
✓
Current Evidence
The breast cancer signal in WHI was from medroxyprogesterone acetate (MPA), a synthetic progestin. Micronized progesterone (the molecule we use) shows a substantially different safety profile. The Asi 2016 meta-analysis (E3N cohort + others) found RR 0.67 for breast cancer with micronized progesterone vs. synthetic progestins. Glaser's data goes further: progesterone (not synthetic progestins) does not increase breast cancer risk. Asi '16Glaser
×
Old Dogma
"Progesterone causes depression."
✓
Current Evidence
For most patients, micronized progesterone is mood-neutral or mood-supportive via GABAergic effects. A subset (estimated 10–20%) experiences paradoxical intolerance. Anxiety, depression, or agitation. This is real and warrants a route change, not dismissal. Do not generalize either way. Brighten
×
Old Dogma
"All progestogens are the same."
✓
Current Evidence
They are not. Micronized progesterone is bioidentical the same molecule the ovary makes. Synthetic progestins (MPA, norethindrone, drospirenone) are structurally different and have different receptor activity, including effects on androgen, glucocorticoid, and mineralocorticoid receptors. The cardiovascular and breast cancer signals attached to "progesterone" in the popular press are almost always traceable to synthetic progestins. NAMS '22
2.3.4Red Flags & Escalation
!
Escalate this week
New or worsening depression / suicidal ideation
Severe anxiety or panic that started with progesterone
Persistent daytime sedation interfering with driving or function
Breakthrough bleeding beyond 6 months on stable regimen (see Bleeding card)
Severe breast tenderness not improving with dose adjustment
Patient skipping doses repeatedly due to side effects (adherence failure)
2.3.5Monitoring Timeline
Timepoint
What Happens
Patient-Facing Framing
Night 1–3
Sedation effect peaks. Some grogginess possible.
"Take it 60–90 minutes before bed. You may feel drowsy at first. That's expected."
Week 1–2
Tolerance to sedation typically develops. Sleep improves.
"Most women find this is their best sleep window."
Week 4–6
If mood symptoms develop, this is when they show.
"If you're feeling more anxious or low, reach out. We have other options."
Month 3
Steady state. Endometrial response established.
"By now your body is adjusted. Spotting should be settling."
Month 6
Symptom and bleeding review. Adherence check.
"We'll review your overall regimen and see if anything needs to change."
2.4Testosterone
Testosterone references across sexes. Female protocols anchor in ISSWSH
and Glaser; male protocols anchor in a structured TRT Patient Agreement
and the TRAVERSE cardiovascular safety data.
2.4.1Women: Quick Reference
Preferred Routes (Women)
Topical Cream / Gel
Compounded, daily application to inner thigh or labial area, with thoughtful transfer precautions. Default first-line.
Subcutaneous Pellets
For established patients who want every-3-to-4-month dosing and consistent serum levels. Glaser protocol baseline.
Sublingual / Buccal Lozenges
Compounded, used selectively. Generally not preferred due to swallowing and loss variability.
Injectable (Cypionate)
Used in select cases. Avoid in patients seeking smooth profiles; the injection profile has more peak-to-trough swing.
Glaser / hormonebalance.org reference protocol
Female pellet baseline
Duration: Pellets last 3–4 months in women, 4–5 months in men. Re-dose at symptom return, not at calendar date.
Pre-pellet labs: FSH, E2, free T, total T. SHBG and DHEA-S helpful.
Symptom coverage: Per Sherwin 1985, testosterone alone relieves menopausal symptoms including hot flashes. Hierarchy is T > T+E2 > E2 > placebo. T-only protocols are clinically viable for many menopausal women. Sherwin '85
Aromatization concern: Add anastrozole (1 mg pellet co-implant or oral) if patient shows excess aromatization signs (breast tenderness, bleeding, mood changes) or has breast cancer history.
VTE risk: Pellets bypass the liver. They do not increase clot risk the way oral estrogens do. Glaser
Voice deepening: Not observed at therapeutic implant doses in Glaser's series. Supratherapeutic doses are a different conversation.
Target ranges (women)
Total testosterone: Upper third of female reference range (~50–70 ng/dL). Some protocols target higher.
Free testosterone: Upper third of female reference range.
SHBG: Important context. Low SHBG means more free T per unit of total T; high SHBG (often from OCP history) sequesters T and may require higher total dosing.
2.4.2Women. Common Concerns
"Will I grow facial hair / get a deeper voice?"
At physiologic dosing. No. Voice deepening is not observed at therapeutic doses in Glaser's published series. Hirsutism (fine facial hair) is a possible side effect that resolves on dose reduction; it's not the irreversible masculinization patients fear. Voice deepening is the marker we watch for, and it's rare and dose-dependent.
"Is testosterone even approved for women?"
No FDA-approved female testosterone product exists in the United States. The ISSWSH 2019 Global Consensus supports the use of approved-male products at female doses, prescribed off-label, for HSDD. Compounded products are also used. This is a normal, evidence-supported off-label prescribing pattern. ISSWSH '19
"I have a history of breast cancer. Is testosterone safe?"
The evidence is more supportive than most patients have been told. Glaser's published data show testosterone pellet (+ anastrozole to block aromatization) is safe and possibly protective in breast cancer survivors. Decreases breast proliferation, lowers recurrence risk, may enhance tamoxifen efficacy. Testosterone has been used to treat breast cancer for over 80 years. Always: provider review of the specific case before any commitment. Glaser
"How long until I feel a difference?"
Libido and energy can improve within 4–6 weeks. Mood, cognition, and body composition changes take longer. Often 3 months for noticeable shift. Pellet patients often describe a "click" 2–3 weeks post-insertion. Reassure patience.
2.4.3Women. Red Flags
!
Review this week
Voice deepening: even subtle. Dose review required.
Acne worsening, scalp hair shedding, or oily skin (androgenic excess)
Clitoral enlargement or discomfort
New breast tenderness or unscheduled bleeding (consider aromatization)
Elite, $375/month: Full concierge model. Priority scheduling, expanded labs, peptide and ancillary integration.
Refill rule: 14-day rule. Patient must request refills with 14 days of supply remaining. Late requests are not emergency requests. Document the date.
Patient Agreement: Signed at onboarding. Covers monitoring requirements, side-effect signaling, and what happens if labs fall outside safe ranges (e.g., hematocrit > 54%).
Target ranges (men)
Total testosterone: Mid-to-upper male reference range (~600–900 ng/dL for symptom relief). Trough levels matter most on injectable protocols.
Free testosterone: Upper reference range.
Estradiol: Monitor. Aromatization drives mood, libido, breast tenderness. Treat with anastrozole only if elevated and symptomatic.
Hematocrit: Watch for > 52% (caution) and > 54% (intervention. Therapeutic phlebotomy or dose reduction).
PSA: Baseline and surveillance per age and risk.
2.4.2Men. Common Concerns
"Does TRT cause heart attacks?"
No. And we now have the trial data to back this up. TRAVERSE (2023) randomized over 5,000 hypogonadal men with cardiovascular risk factors to testosterone or placebo. Testosterone was non-inferior to placebo for major adverse cardiovascular events (MACE). The decades-old cardiovascular fear, which came from observational data and the FDA black-box period, did not survive a properly powered RCT. TRAVERSE '23
Watch points from TRAVERSE: small but real signals for atrial fibrillation, pulmonary embolism, and acute kidney injury. Worth monitoring; not deal-breakers.
"Will TRT shrink my testicles / kill my fertility?"
Exogenous testosterone suppresses LH/FSH and shuts down testicular testosterone and spermatogenesis. Testicular atrophy is common with sustained TRT. For fertility preservation: hCG (250–500 IU SC 2–3×/week) maintains intratesticular testosterone and spermatogenesis. Enclomiphene is an alternative for men who want endogenous T preserved without exogenous TRT.
"My estrogen is too high. Should I take anastrozole?"
Not automatically. Estradiol is critical for male bone, mood, libido, and cognition. Suppressing it aggressively causes its own problems. Anastrozole is used only when E2 is elevated and the patient has aromatization symptoms (breast tenderness, water retention, mood lability). Asymptomatic high E2 is not always pathological.
"What about prostate cancer risk?"
Modern evidence does not support the historical fear that TRT causes or accelerates prostate cancer. The 1940s "saturation model" data has been substantially revised. Monitor PSA per age-appropriate schedule and act on changes. Not on testosterone level alone.
2.4.3Men. Red Flags & Escalation
!
Same-day or this-week escalation
Chest pain, palpitations, shortness of breath, or new-onset cough (cardiac / PE signals)
One-sided leg swelling or calf pain (DVT)
New irregular heartbeat or "fluttering" (atrial fibrillation. TRAVERSE signal)
Hematocrit reported as > 54% on routine labs
Significant breast enlargement / tenderness (gynecomastia)
New mood instability, aggression, or sleep disruption
Injection site reactions (see Triage sub-tab. Antihistamine test applies)
2.4.4Men. Adjunct Therapies
Adjunct
When
Typical Dose
Notes
Anastrozole
Elevated E2 + symptoms
0.25–0.5 mg 2×/week
Lowest effective dose. Crashing E2 is harmful.
hCG
Fertility / testicular preservation
250–500 IU SC 2–3×/week
Maintains intratesticular T and spermatogenesis.
Enclomiphene
Alternative to TRT (preserves HPG axis)
12.5–25 mg daily or QOD
For men prioritizing fertility / natural production.
Therapeutic phlebotomy
Hematocrit > 54%
Per blood bank protocol
Donate blood. Reassess HCT in 6–8 weeks.
2.5Thyroid
Thyroid often masquerades as menopause, and menopause often masquerades as
thyroid. The first job is to know which is which. The full workup, the
treatment thresholds, and where the ATA 2024 update parts ways with old
"TSH-only" management.
2.5.1Beyond TSH: The Full Workup
What to Order
TSH
The screening test. Sensitive, but not sufficient on its own.
Free T4 (fT4)
What the gland is releasing.
Free T3 (fT3)
The active hormone at tissue level. Often missing on standard panels.
Reverse T3 (rT3)
A depressed fT3:rT3 ratio points to peripheral conversion problems: stress, undernutrition, chronic illness.
TPO + TGAb Antibodies
Autoimmune thyroiditis (Hashimoto's). Often present with normal TSH and symptoms.
TSH alone misses peripheral conversion issues, autoimmune disease in the euthyroid phase, and central hypothyroidism. A normal TSH does not rule out a thyroid problem.
Marker
Optimal Range (functional)
Standard Lab Range
TSH
1.0–2.0 µIU/mL
0.45–4.5 µIU/mL
Free T4
1.1–1.5 ng/dL (upper half)
0.8–1.8 ng/dL
Free T3
3.2–4.2 pg/mL (upper half)
2.3–4.2 pg/mL
Reverse T3
< 15 ng/dL ideally
9.2–24.1 ng/dL
fT3:rT3 ratio
> 20 (some advocate > 14)
Not standard
TPO Ab
Negative
< 9 IU/mL
2.5.2Treatment Thresholds
Overt hypothyroidism
TSH > 10 µIU/mL with low fT4 → treat. Levothyroxine (T4) first-line. Target TSH within reference, with attention to symptoms and fT3.
Subclinical hypothyroidism
TSH 4.5–10 µIU/mL with normal fT4 → individualize. ATA 2014 was conservative ("consider treatment if TSH > 10 or symptomatic"); modern functional practice often treats earlier when symptoms are present, TPO is positive, or fertility/pregnancy is a goal. ATA '14
Persistent symptoms on T4 alone
The ATA 2024 update opened the door to T4/T3 combination therapy for patients persistently symptomatic on adequate T4. A reversal of the longstanding T4-only orthodoxy. ATA '24
Options: liothyronine (synthetic T3) added to T4, or natural desiccated thyroid (NDT: Armour, NP Thyroid). NDT has both T4 and T3 in a ~4:1 ratio.
NDT: what to know
Patients ask about NDT often. It's a viable option for many. Particularly those who feel "TSH is fine but I don't feel right." Some patients respond better to NDT than to T4 alone. Watch for: TSH suppression (some over-respond), fT3 spikes (timing matters. Take in AM), and supply-chain inconsistency (Armour has had reformulation history; NP Thyroid is the alternative most clinicians prefer now).
2.5.3Common Concerns
"My TSH is normal but I feel terrible."
Most common thyroid presentation in functional practice. TSH-only management misses peripheral conversion issues. Run the full panel: fT4, fT3, rT3, antibodies. Patient often has either (a) low fT3 with normal TSH (poor conversion), (b) positive antibodies with normal labs (early Hashimoto's), or (c) elevated rT3 from chronic stress / cortisol / illness.
"Is this thyroid or menopause?"
Often both, often overlapping. Fatigue, weight gain, brain fog, hair changes, mood, cold intolerance all appear in both. Work them up together. Both can be true.
"Can HRT affect my thyroid medication?"
Yes. Oral estrogen raises thyroxine-binding globulin (TBG), reducing free T4 availability. Patients starting oral estrogen may need T4 dose increase. Transdermal estrogen bypasses this another reason to prefer the patch. Recheck TSH and free hormones 6–8 weeks after any HRT change in a thyroid patient.
"Why iodine / selenium / etc.?"
Nutrient co-factors matter. Selenium supports T4→T3 conversion. Iodine is essential but contentious (excess can trigger autoimmune flare in some). Zinc, ferritin, and vitamin D all contribute. Test before supplementing.
2.5.4Red Flags & Escalation
!
Same-day escalation
Palpitations, chest pain, or atrial fibrillation on thyroid medication (over-replacement)
Severe agitation, insomnia, weight loss (thyrotoxicosis / Graves')
Severe fatigue, cognitive slowing, cold intolerance. Uncontrolled severe hypothyroidism
First recheck after starting or changing thyroid med
TSH, fT4, fT3. Wait this long. TSH takes ~6 weeks to stabilize.
Every 8 weeks
Until stable on dose
Same panel. Adjust per symptoms + labs.
Every 6 months
Stable patient maintenance
TSH, fT4, fT3. Antibodies annually if Hashimoto's.
Annual
Full review
Full panel + clinical assessment.
After any HRT change
Re-equilibration
Recheck at 6–8 weeks. TBG shifts on oral E2.
Note on functional monitoring
Monitor functionally, not just by TSH. Patient symptoms guide titration as much as numbers. A patient with TSH 1.8 and persistent symptoms is not "done". Look further (fT3, rT3, antibodies). A patient with TSH 0.3 and feeling great may not need a dose reduction if fT4/fT3 are in range and they're not symptomatic. Numbers in context.
2.6Injection Reactions
The deep reference behind the Injection Site Reaction triage card. Three
bodies of knowledge: the testosterone / carrier-oil story, the peptide /
reconstitution story, and the universal triage logic that applies to both.
Most injection-site reactions are histamine-mediated and resolve with a
formulation or technique change. The job is separating those from the
infection-or-systemic picture that needs escalation.
The reaction is frequently to the vehicle, not the hormone. Carrier oil, benzyl
benzoate, and benzyl alcohol are all independent sensitizers. And the variable
you can most easily change.
What's Happening Under the Skin
Formulation, Not Just Hormone
Injectable testosterone is never only testosterone. The carrier oil, benzyl benzoate (co-solvent), and benzyl alcohol (preservative) are all potential sensitizers, often more so than the hormone itself.
Mast Cell Degranulation
Subcutaneous fat is rich in mast cells. A foreign substance triggers histamine release: the itch, hives, and redness. This is immune surveillance, not necessarily a true allergy.
Two Distinct Pathways
Type I (minutes to 2 hrs) is IgE-mediated and implies pre-existing sensitization. Type IV (8–24 hrs) is T-cell mediated and develops over weeks. The timing tells you which.
Carrier Oil
Common Formulation
Viscosity
Inflammatory Risk
Clinical Note
Cottonseed
Depo-Testosterone (Pfizer), most generic TC
High
Highest
Default US generic; cotton-allergic patients must switch
Sesame
Delatestryl (TE), many compounded
Med–High
Moderate
FDA allergen labeling required; avoid in sesame allergy
Grapeseed
Compounded TC / TE
Low
Low
Preferred for SubQ; fewest site reactions reported
MCT (coconut)
Compounded formulations
Very Low
Hypoallergenic
Best tolerated; ideal for reactive patients
Ethyl oleate
Compounded TC
Very Low
Low
Fastest absorption; rare EO-specific sensitivity possible
Castor (Aveed)
Testosterone undecanoate only
Very High
POME risk
FDA mandates 30-min post-injection observation
All commercial formulations also contain benzyl alcohol and benzyl benzoate. Both independent sensitizers, regardless of oil.
Timing Differential: Diagnostic Question #1
Minutes – 2 hours (Type I, IgE-mediated): First injection or new vial. Pre-existing sensitization, likely to carrier oil (sesame, cottonseed) or benzyl alcohol. Rare, but can escalate to systemic symptoms. Watch it.
8 – 24 hours (Type IV, T-cell mediated): Fine for the first few weeks, then begins. Early injections prime the immune system; later ones trigger the response. Rash lingers 5–7 days and peaks the next morning.
Weeks – months (progressive sensitization / vial issue): Tolerated fine, then reactions began. Repeated SubQ dosing in one zone sensitizes the tissue; rising estradiol lowers the mast cell threshold; a new lot or vial is another trigger.
The new-vial question
Did the reaction begin exactly when the patient opened a new vial or switched pharmacies? Compounding batches vary. Benzyl benzoate concentration, oil refinement, and trace impurities all differ between lots. A cloudy vial, visible particles, or off-smell means discard immediately.
Management Protocol · The Six Levers
1
Don't Scratch
Scratching degranulates more mast cells and spreads histamine through surrounding tissue. Ice instead.
2
Cold Compress
Cold pack (not ice directly on skin) for 10–15 min post-injection. Constricts vessels, slows histamine spread.
3
Oral Antihistamine
Loratadine or cetirizine, both non-drowsy, long-acting H1 blockers. Pre-dose before injection when the reaction is predictable.
4
Rotate Sites
Move at least 2–3 cm between injections. Alternate abdominal quadrants, thighs, glutes. Never the same spot within a week.
5
Switch the Oil
Reactive to cottonseed? Move to compounded TC in grapeseed or MCT. Change one variable at a time. Most reactions resolve here.
6
Check Estradiol
Rising E2 amplifies mast cell activity. If reactions began as hormones optimized, check labs. Anastrozole may reduce reactivity.
Peptide reactions look like testosterone reactions but the mechanism and the
variables differ. The reconstitution carrier, peptide charge, and injection
depth all matter. And the key receptor is MRGPRX2, a
pseudo-allergic pathway that fires without any IgE involvement.
Why Peptides Trigger Mast Cells
MRGPRX2 Activation
Many peptides, especially cationic (positively charged) ones, activate the MRGPRX2 receptor on skin mast cells, releasing histamine without IgE. Not a true allergy.
The Benzyl Alcohol Problem
Bacteriostatic water contains benzyl alcohol as preservative. Many reactions are to this, not the peptide. The water test isolates the variable definitively.
The Depot Effect
SubQ peptides pool in fat, giving histamine more time to activate surrounding nerves. The spreading, crawling itch is the depot, not a systemic reaction.
Relative reactivity by peptide
Higher reactivity: GHK-Cu (cationic, high MRGPRX2 activation) · MOTS-c (+3 net charge, aromatic residues) · CJC-1295 / Tesamorelin (confirmed pseudo-allergic via MRGPRX2, 44-AA size).
Moderate: BPC-157 (also pH-variable by manufacturer) · Ipamorelin (mild, generally well tolerated) · TB-500 (may do better IM than SubQ).
Lower: Sermorelin (mild, transient, occasional flushing) · Thymosin Alpha-1 (low; immune modulation may cause a mild early reaction).
Reactivity reflects relative histamine response, not contraindication. Most are manageable with reconstitution and technique changes.
Reconstitution Variables · The Six Dials
BAC vs. Sterile Water
Bacteriostatic water contains benzyl alcohol, a mast cell trigger. Sterile water removes it, but the vial must be used immediately once opened.
Dilution Volume
Concentration-dependent response is real. Diluting with 3–4 mL instead of 1–2 mL spreads the dose and reduces activation at any single point.
pH of the Solution
Some peptides (BPC-157, NAD+) are acidic. An acidic bolus into pH-7.4 tissue causes direct chemical irritation, independent of immune response.
Injection Speed
Slow, steady injection over 10–15 seconds reduces pain and inflammatory response. Fast injection creates pressure trauma and depot irregularity.
Temperature
Refrigerator-cold solution shocks tissue and amplifies the local inflammatory response. Bring to room temperature first.
Blend vs. Single Peptide
A blend makes it impossible to isolate the reactant. Single-ingredient vials are essential for detective work once reactions begin.
The Water Test: Isolate the Variable
Step 1. Inject 0.2 mL of BAC water only, no peptide, in a different site (outer thigh). Same hive? → reacting to benzyl alcohol, not the peptide.
Step 2. If BAC water is clean, inject the peptide alone in the new site. Same reaction? → peptide-specific; isolate which one.
Step 3. Switch abdomen → outer thigh. Thigh tissue is often less reactive. No reaction → site-specific sensitization, not systemic.
Step 4. If a blended vial, separate into single-ingredient vials and test one per day across successive days to identify the trigger.
Histamine Load Reduction: DAO Enzyme Support
Diamine oxidase (DAO) is the primary histamine-degrading enzyme. Low DAO means higher baseline histamine and a lower threshold for mast cell reactions. Supports: vitamin C 1,000–2,000 mg/day, vitamin B6 as P5P 50–100 mg/day, copper 1–2 mg/day, and quercetin (a natural mast cell stabilizer). Estradiol status also strongly upregulates mast cell sensitivity. Check E2 if reactions are worsening over time.
The decision framework that applies regardless of what was injected. The
threshold for alarm is systemic symptoms or tissue breakdown. Not the
presence of a welt.
Green: manage at home
Annoying, not alarming. Itch only (no heat, no pain), hives local to the site, onset 30 min to several hours, resolves fully in 24–48 hrs, same pattern as prior injections, no fever or spread beyond the zone. Action: cold compress, oral antihistamine, log it, modify technique next dose.
Yellow: contact provider
Escalating, needs investigation. Worsening with each dose, timing shifted earlier, hives spreading beyond the zone, lasting longer than 48–72 hrs, started with a new vial/lot, or itch now with mild warmth. Action: pause protocol, formulation review, oil or carrier switch, possible antihistamine pre-treatment.
Red: seek care now
This is not a histamine story. Heat + pain at the site, spreading redness beyond 5 cm, fever / chills / flu-like symptoms, pus or abscess or skin breakdown, wheezing or throat tightening, dizziness or sense of impending doom, tender regional lymph nodes. Action: respiratory/systemic symptoms → 911; heat + pain + fever → urgent care or ED. Do not wait.
The antihistamine diagnostic test
Have the patient take a standard dose of loratadine or cetirizine when the reaction begins, then wait 60–90 minutes.
Significantly better → confirms a histamine-mediated response. This is a formulation or technique issue, not an infection. Manage and modify.
No improvement → something else is happening. Heat, pain, or fever suggests infection or cellulitis. Evaluate. Don't just add more antihistamine.
The itch-vs-heat rule
Itch without heat is the histamine story. Mast cells fired, immune surveillance working, uncomfortable but self-limiting. Manage locally and adjust protocol.
Heat + pain is a different conversation. Possible early cellulitis, abscess, or deep-tissue inflammation. Requires clinical evaluation, not more antihistamine.
Coaching the Anxious Patient: Data vs. Rumination
The data to gather: Time it (minutes = Type I, hours = Type IV, days = sensitization; the clock is diagnostic). Run the antihistamine test. Compare to prior reactions (same as last week, same resolution = management issue, not escalation). Check temperature by touch (warm and itchy = histamine; hot, tender, swollen = call).
What anxiety does: amplifies perceived severity (stress hormones genuinely raise mast cell sensitivity), drives 2 a.m. forum-reading on a textbook histamine reaction, prompts abandoning a working protocol over one mild self-resolving hive, and escalates a 2-cm non-hot welt to urgent care. Coach the patient to triage on the data, not the worry.
The bottom line to convey: a hive that itches and fades within 24 hours is the immune system doing exactly what it should: reacting, flagging, resolving. The alarm threshold is systemic symptoms or tissue breakdown, not the welt itself.
Systemic symptoms: dizziness, throat changes, shortness of breath
Any uncertainty: better to field the call than miss escalation
03
Protocols
How to start someone. The upstream logic Chairside doesn't cover.
Terrain before hormones, the initiation sequence, the route and safety forks.
When you need molecule-level dosing detail, each pathway links down to the
matching Chairside reference rather than repeating it.
3.1The Terrain-First Sequence
Hormone optimization layered onto untreated terrain underperforms. Inflammation,
poor metabolic flexibility, and nutrient gaps blunt the response and amplify side
effects. Address the five pillars first. Then the hormone work lands on prepared ground.
The Core Principle
Treat the soil before you plant the seed.
A patient strong across all five terrain pillars tolerates and responds to hormone therapy predictably. Weakness in any pillar gets addressed in parallel, never ignored. Every initiation starts with a terrain read.
The Five Terrain Pillars
Inflammation
hsCRP, ferritin, fibrinogen, homocysteine. Chronic inflammation lowers the mast cell threshold, blunts receptor sensitivity, and worsens injection-site reactivity.
Hormonal Signaling
Sex hormones, thyroid cascade, cortisol rhythm. The target of optimization, read in context of the other four.
Nutrient Availability
Vitamin D, B12/folate, ferritin, magnesium, zinc. Cofactors for hormone synthesis, conversion, and receptor function.
Sleep, HRV, cortisol slope. Determines whether the body acts on the optimization signal or stays stuck in catabolic stress.
1
Terrain Read
Full functional panel across the five pillars. Use the Lab Review tab to score and pattern-match. The goal is a terrain baseline, not just a hormone snapshot. You decide what to fix before and alongside hormone initiation.
2
Foundation First
Address the limiting pillars before or concurrent with hormone start: correct vitamin D and ferritin, restore metabolic flexibility, stabilize sleep and cortisol, lower inflammatory load. The Seven Laws of Health (sleep, air, food, water, rest, movement, love) are the daily behavioral layer underneath the biochemistry.
3
Sequence the Hormone Work
Only once the foundation is moving do you layer hormone optimization. Female or Male pathway. Terrain-prepared patients titrate faster, tolerate better, and hold gains longer.
4
Re-Read & Iterate
Re-score terrain at each follow-up. Track pillar movement, not just hormone levels. A rising hormone level on a still-inflamed terrain is a warning, not a win.
3.2Female HRT Pathway
Staging → baseline labs → the initiation decision → route → titration by symptom.
Anchored in the Glaser subcutaneous-pellet model and the Sherwin hierarchy
(testosterone alone relieves nearly all menopausal symptoms). For molecule-level
detail. Formulations, dose targets, monitoring. Drop into the Chairside hormone tabs.
1
Stage Her. STRAW+10
Place the patient on the reproductive-aging continuum: reproductive → menopausal transition (early/late peri) → postmenopause. Staging drives whether you expect cyclic vs. continuous regimens and how you frame the conversation.
2
Baseline Labs
Pre-initiation panel:
FSHEstradiolFree TTotal TSHBGDHEA-S
plus terrain markers from 3.1. FSH + E2 confirm menopausal status; free/total T and SHBG set the testosterone starting point.
3
The Initiation Decision
Use the fork below to determine the starting regimen based on her symptom picture and whether a uterus is present.
4
Titrate by Symptom, Monitor by Cadence
Re-dose pellets at symptom return (≈3–4 months in women), not by the calendar. Recheck labs and symptoms; adjust toward the upper-third female range for free and total T. Full monitoring timelines live in Chairside.
Starting regimen. What does she need?
Testosterone-only
Per the Sherwin hierarchy and Glaser model, testosterone alone relieves nearly all menopausal symptoms including hot flashes. No progestin is required when no estrogen is prescribed. Pre-labs: FSH, E2, free + total T. Add anastrozole if excess aromatization signs or breast-cancer history. Pellets bypass the liver. No added clot risk. See Chairside 2.4 (Testosterone · Women) for dosing detail.
Estrogen needed
For genitourinary symptoms or vasomotor symptoms not covered by testosterone alone. Prefer transdermal estradiol (VTE-neutral) for systemic need; vaginal estriol or low-dose vaginal estradiol for GSM. Estradiol pellets are avoided in this model. If a uterus is present, estrogen obligates progesterone. See the next branch. See Chairside 2.2 (Estradiol).
Progesterone for endometrial protection
Uterus present + any systemic estrogen = progesterone is mandatory for endometrial protection. Oral micronized progesterone at bedtime is the default (GABAergic, sleep-supportive). Watch for paradoxical intolerance → vaginal route or LNG-IUD. See Chairside 2.3 (Progesterone).
3.3Male HRT Pathway
Biochemical confirmation → risk → route → fertility branch → estradiol management →
the hematocrit safety gate. TRAVERSE (2023) put the cardiovascular fear to rest;
the live safety variable is HCT. Molecule detail and adjunct dosing live in Chairside 2.4.
1
Confirm Biochemically
Two morning total testosterone draws below range, plus symptoms. Don't treat a number alone or a symptom alone.
Total T ×2 AMFree TSHBGLHFSHEstradiolPSACBC/HCT
2
Risk Assessment
TRAVERSE (2023): testosterone was non-inferior to placebo for major adverse cardiovascular events in hypogonadal men with CV risk. Cardiovascular history is not a hard contraindication. Baseline PSA and hematocrit; flag erythrocytosis risk and uncontrolled OSA.
3
Route & Fertility. Use the forks below
Route selection depends on what the patient wants from the profile; fertility intent changes the entire approach (exogenous T suppresses spermatogenesis).
4
Monitor. E2 & the HCT Gate
Trough total T toward mid-upper range. Manage estradiol only if elevated and symptomatic. Hematocrit is the recurring safety checkpoint. See the gate below.
Route selection. What fits the patient?
Injectable cypionate / enanthate
Most common: predictable, titratable, affordable. Weekly or twice-weekly SubQ/IM smooths peaks and troughs. Best when the patient wants dose control and lab-driven titration. Trough is the meaningful measurement. See Chairside 2.4 (Men).
Subcutaneous pellets
Every 4–5 months in men; consistent levels, no weekly self-injection. Best for adherence-focused patients who want "set and forget." Re-dose at symptom return. See Chairside 2.4 (Men).
Topical gel
Daily application; physiologic rhythm. Transfer precaution is the real constraint. Children and partners. Best for needle-averse patients who can manage transfer discipline. See Chairside 2.4 (Men).
Does he want to preserve fertility?
Fertility-preserving path
Exogenous testosterone suppresses LH/FSH and spermatogenesis. To preserve: hCG (maintains intratesticular testosterone) alongside or instead of TRT, or enclomiphene to drive endogenous production without exogenous T. Discuss sperm banking before starting if fertility is near-term. Adjunct dosing in Chairside 2.4.
Standard TRT
Proceed with the selected route. Counsel that testicular atrophy and suppressed fertility are expected; reversibility varies and isn't guaranteed. hCG can still be added for testicular volume / well-being if desired.
Hematocrit safety gate: check every monitoring draw
HCT > 52% → caution; investigate (dose, OSA, dehydration, smoking). HCT > 54% → intervene: dose reduction, route change toward smoother delivery, or therapeutic phlebotomy. This is the recurring hard checkpoint of male TRT. It does not resolve on its own.
3.4Adjacent Protocols
The terrain pillars that aren't sex hormones. Same initiation logic. Read, prepare,
sequence, re-read. These are scaffolded here; the depth fills in as each protocol locks.
Thyroid
Often the limiting pillar behind a stalled hormone response. Work it up beyond TSH (free T4, free T3, reverse T3, antibodies) before assuming the sex-hormone axis is the problem. Full reference, treatment thresholds, and the ATA 2024 T4/T3 update live in Chairside 2.5.
Cardiometabolic / ASCVD
Metabolic flexibility is a terrain pillar; ApoB and insulin resistance distort the entire hormone picture. The initiation logic mirrors 3.1. Read the metabolic markers, address the foundation, then layer.
Coming soonA dedicated cardiometabolic / ASCVD pathway — ApoB targets, the 2026 ACC/AHA lipid-lowering thresholds, and the insulin-resistance connection — is in development and will be added to this section.
Insulin Resistance · Gut · Medical Weight Loss
Each follows the same terrain-first pattern. GLP-1 management, gut-restoration sequencing, and the metabolic-weight pathway are natural next builds.
Coming soonInsulin-resistance, gut-restoration, and medical-weight-loss pathways are in development and will be added as a set, consistent with the hormone protocols.
04
Practice
The conversion playbook. How an aesthetic / wellness practice adds functional
medicine without it feeling like a sales pitch. This is the model, not a price
list: the framework is yours to teach, the numbers are yours to set. The one
principle underneath all of it. Assign value to your time, your expertise,
and your level of care. Undercharging for functional medicine is almost
always undervaluing the thinking, not the procedure.
4.1Value & Pricing
Price the thinking, not the procedure. An aesthetic practice prices by the unit:
per syringe, per area, per session. Functional medicine prices by judgment. The
workup, the interpretation, the longitudinal relationship. The conversion fails
when a practice carries aesthetic unit-pricing instincts into FM and gives away
the cognitive work for free.
The Principle
Assign value to your time, your expertise, and your level of care.
Undercharging for functional medicine is almost always undervaluing the thinking, not the procedure. The conversion fails when a practice carries aesthetic unit-pricing instincts into FM and gives away the cognitive work for free.
Time
A real consult and lab review is 45–90 minutes of focused work, plus prep and documentation the patient never sees. Price below that floor and every FM patient is subsidized by the aesthetic side.
Expertise
The interpretation is the product. Anyone can draw labs. The value is the pattern recognition, the terrain reading, the protocol design. That is what the patient pays for, not the blood draw.
Level of Care
Longitudinal FM is a relationship, not a transaction. Re-tests, message access, protocol adjustments. That ongoing care is what recurring revenue captures. Price the relationship, not just the visit.
Three Pricing Architectures · Pick the Model First
À la Carte
Consult fee + lab review + per-protocol pricing. Simplest to start, lowest patient commitment, but no recurring revenue. Best as an entry point or one-off consult.
Package / Program
Consult + labs + first protocol + a defined follow-up window, sold as one price. Captures the full initiation value upfront and sets the expectation that FM is a process.
Membership
Monthly or annual, a defined cadence of visits, labs, and access. Matches the level-of-care principle: recurring care, recurring revenue. Hardest to launch, most durable once running.
Which pricing architecture fits the practice?
À la carte. Entry model
Use when the practice is testing FM demand or converting cautiously. Price each component to stand on its own. The consult fee must cover the cognitive time whether or not the patient buys a protocol. The risk: no recurring revenue and patients treat FM as a one-off. Plan a path to migrate engaged patients into a package or membership.
Package. Initiation model
Bundle the full initiation (consult + baseline labs + first protocol + a defined follow-up window) into one price that captures the entire startup value. Sets the expectation that FM is a process. Strongest as the default offer for a new FM patient coming off the aesthetic side.
Membership. Relationship model
Monthly or annual; a defined cadence of visits, labs, and access. This is the architecture that matches the level-of-care principle and builds durable recurring revenue. Requires the most operational discipline (defined inclusions, refill rules, cadence). See the TRT three-tier reference model in Chairside 2.4 for one worked example of tier structure.
Your numbersThis framework deliberately carries no dollar figures. Pricing is market-, scope-, and region-specific, and it's yours to set. If you want a worked example built in (a sample tier ladder with placeholder figures a licensee can overwrite), tell me the structure you teach and I'll lay it in as an illustrative model, clearly marked as an example.
4.2The Conversion
Turning an aesthetic patient into a functional-medicine patient without it
feeling like a sale. The bridge is clinical, not commercial: the same patient
who came for a cosmetic result has an internal terrain driving that result.
Name the connection, and the FM consult becomes the obvious next step rather
than an upsell.
The Bridge: Aesthetics Is the Symptom, Terrain Is the Cause
The aesthetic patient is already paying for outcomes. The conversion reframes those outcomes as downstream of internal health: skin quality, recovery, how long results last, how they feel, all terrain-driven. You are not adding a service; you are explaining why the result they already want depends on the thing you actually treat.
1
Notice the Opening
The aesthetic visit surfaces FM signals constantly: fatigue, poor sleep, weight changes, slow healing, mood. The opening is the patient mentioning one, unprompted. Train the team to hear it.
2
Name the Connection
Connect the cosmetic concern to the internal driver, in the patient's language. "The reason your results don't last as long as you'd like is partly what's happening underneath. And that's something we can actually look at." No pressure, just a clinical observation.
3
Offer the Look, Not the Sale
The next step is a consult or a baseline panel. A look, not a commitment to a program. Lower the threshold to the first FM touch; the value sells itself once the terrain data is in front of them.
4
Let the Data Convert
In the consult, the labs and terrain read do the work. The patient sees their own numbers and the FM relationship becomes self-evident. This is why the consult must be priced for the cognitive time. It is the conversion event.
The line that keeps it clinical, not commercial
The conversion stays ethical and comfortable as long as the FM offer follows a genuine clinical signal the patient raised. Never a script applied to every patient regardless of presentation. If there's no real clinical opening, there's no conversion to make. That discipline is what keeps it from feeling like a sales pitch, and it's what protects the practice's trust.
Your scriptsThe exact consult language, objection handling, and the specific bridge phrases you use are yours. The flow above is the structure; if you want your actual scripts built in as a reference layer for your team or licensees, send them and I'll format them into the toolkit's clinical-script style.
4.3Patient Flow
Intake, consent, and expectation-setting. The structure that makes the FM
relationship run cleanly from the first touch. Functional medicine has a longer
arc than an aesthetic visit; the flow has to set that expectation early or the
patient measures a months-long process against a same-day-result yardstick.
1
Intake. Capture the terrain, not just the complaint
FM intake goes wider than aesthetic intake: symptoms across systems, history, lifestyle, the Seven Laws baseline. The intake itself signals that this is a different kind of care. Comprehensive, not transactional.
2
Consent. Scope, off-label, and expectations
Functional and longevity medicine often involves off-label prescribing, compounded formulations, and protocols outside conventional guidelines. Consent must name that clearly. This is a legal and scope question. The structure here is workflow guidance, not legal advice; confirm your consent language with your own counsel.
3
Expectation-Setting. The arc, not the appointment
Set the timeline explicitly: terrain takes time to move, the first re-test is weeks or months out, optimization is iterative. A patient who understands the arc stays engaged through the lag before results; one who doesn't churns at the first slow month.
4
Follow-Up Cadence. The relationship rhythm
Define the cadence up front (initial re-test window, ongoing visit frequency, message-access rules). The cadence is what the membership model prices; even in à la carte, a defined rhythm is what turns a one-off consult into ongoing care.
Your formsYour actual intake forms, consent documents, and expectation-setting scripts are practice-specific (and the consent piece is jurisdiction-specific). The flow above is the structure; supply your documents and I'll integrate references or formatted versions, but consent language should always be confirmed with your counsel.
4.4Operations
The boring-but-essential layer. Documentation, delegation, and what the
prescriber must keep versus what the team can carry. The conversion and the
pricing don't survive contact with a busy practice unless the operational
scaffolding holds them up.
What to keep vs. what to delegate
The prescriber keeps: the clinical judgment: terrain interpretation, protocol design, dose decisions, the conversion consult itself. This is the cognitive work that justifies the pricing; it cannot be delegated without becoming the thing patients stop paying a premium for.
The team carries: intake collection, lab ordering and tracking, refill workflows within defined rules, follow-up scheduling, the membership-cadence mechanics, and first-line patient messaging. The more of this the team owns cleanly, the more consults the prescriber can run.
Documentation patterns
Functional medicine documentation has to capture longitudinal terrain movement, not just single-visit notes. The value is in the trend. A documentation pattern that surfaces "what changed since last visit" turns every follow-up into a data-driven encounter and makes the recurring relationship visible to the patient.
The operational discipline that protects the model
Refill rules, lab cadence, and membership inclusions must be defined and enforced, or the membership model quietly bleeds value (the 14-day refill rule in the Chairside TRT reference model is one worked example). Late requests aren't emergencies; undefined inclusions become unlimited inclusions. The discipline is what keeps recurring revenue actually recurring.
Your SOPsYour specific delegation map, documentation templates, and staff scripts are operational IP. The patterns above are the framework; supply your SOPs and I'll build them into the toolkit as a reference layer for your team or licensees.
